Earnings Call Summary | Ligand Pharmaceuticals(LGND.US) Q1 2024 Earnings Conference
Earnings Call Summary | Ligand Pharmaceuticals(LGND.US) Q1 2024 Earnings Conference
The following is a summary of the Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript:
以下是Ligand Pharmicals Incorporated（LGND）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Ligand Pharmaceuticals reported a Q1 2024 revenue of $31 million compared to $44 million in Q1 2023, largely attributed to a $15 million milestone earned in Q1 2023.
Q1 2024 royalty revenue increased 8% to $19.1 million from $17.6 million in Q1 2023, driven by strength in FILSPARI, Rylaze, Kyprolis, and Vaxneuvance.
Captisol sales were $9.2 million, a drop from $10.6 million in Q1 2023.
Ligand reported a GAAP net income from continuing operations in Q1 2024 of $86.1 million compared to $43.6 million in the prior year's quarter.
The company reaffirmed its 2024 financial guidance with royalty revenue in the range of $90-95 million and Captisol sales in the range of $25-27 million.
They predict a compound annual growth rate of over 20% in royalty revenue and over 25% in adjusted EPS over the next five years.
Ligand Pharmicals报告称，2024年第一季度收入为3,100万美元，而2023年第一季度为4,400万美元，这主要归因于2023年第一季度实现了1500万美元的里程碑。
受FILSPARI、Rylaze、Kyprolis和Vaxneuvance强劲的推动，2024年第一季度的特许权使用费收入从2023年第一季度的1,760万美元增长了8％，至1,910万美元。
Captisol的销售额为920万美元，低于2023年第一季度的1,060万美元。
Ligand报告称，2024年第一季度来自持续经营业务的GAAP净收入为8,610万美元，而去年同期为4,360万美元。
该公司重申了其2024年的财务指导，特许权使用费收入在9000万至9500万美元之间，Captisol的销售额在2500万至2700万美元之间。
他们预测，未来五年特许权使用费收入的复合年增长率将超过20％，调整后的每股收益将超过25％。
Business Progress:
业务进展：
Ligand announced Pelthos Therapeutics' establishment to commercially offer ZELSUVMI by year-end.
The FDA approved ZELSUVMI, a first-in-class medication for molluscum contagiosum treatment.
Key 2024 catalysts include potential FDA approval of Merck's V116 and Verona's Ensifentrine.
Agenus partnership involving a $75 million upfront investment was announced, significantly boosting Ligand's portfolio exposure to immuno-oncology.
The FDA granted Travere priority review for FILSPARI, with expected PDUFA date in September 2024.
Verona Pharma prepares for ensifentrine's launch following potential approval in June.
Ligand is exploring strategic partnerships and considering spinning out its Pathios business.
Ligand宣布成立Pelthos Therapeutics，将在年底之前对ZELSUVMI进行商业化销售。
美国食品药品管理局批准了ZELSUVMI，这是一款治疗传染性软疣的同类首款药物。
2024年的关键催化剂包括美国食品药品管理局可能批准默克公司的V116和维罗纳的Ensifentrine。
宣布了涉及7500万美元预付投资的Agenus合作伙伴关系，这极大地增加了Ligand在免疫肿瘤学领域的投资组合。
美国食品和药物管理局批准了特拉弗雷对FILSPARI的优先审查，预计PDUFA的日期为2024年9月。
维罗纳制药公司可能在6月获得批准后，为ensifentrine的推出做准备。
Ligand正在探索战略合作伙伴关系，并考虑分拆其Pathios业务。
More details: Ligand Pharmaceuticals IR
更多详情： Ligand 制药公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。